- Home
- M vs PCVX Comparison
M vs PCVX Comparison
Compare M & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | M | PCVX |
|---|---|---|
| Founded | 1830 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 7.0B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | M | PCVX |
|---|---|---|
| Price | $23.97 | $66.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | $23.18 | ★ $117.30 |
| AVG Volume (30 Days) | ★ 5.7M | 3.1M |
| Earning Date | 12-02-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | ★ 12.08 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $22,621,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.69 | $39.87 |
| 52 Week High | $26.59 | $90.75 |
Technical Indicators
Market Signals| Indicator | M | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 62.79 | 55.52 |
| Support Level | $21.81 | $50.26 |
| Resistance Level | $24.02 | $90.75 |
| Average True Range (ATR) | 0.83 | 4.79 |
| MACD | 0.11 | 0.59 |
| Stochastic Oscillator | 96.24 | 30.63 |
Price Performance
Historical ComparisonAbout M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.